AG
DCPH

Aperio Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Aperio Group’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,860
Closed -$231K – 2396
2020
Q2 		$231K Buy
+3,860
New +$206K ﹤0.01% 2136
2020
Q1 		– Sell
-3,401
Closed -$212K – 2410
2019
Q4 		$212K Buy
+3,401
New +$162K ﹤0.01% 2186
2019
Q3 		– Sell
-123
Closed -$3K – 2826
2019
Q2 		$3K Buy
+123
New +$2.88K ﹤0.01% 2901

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aperio Group's DCPH Position: Q3 2020 in Review

Aperio Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2020, closing a stake of 3,860 shares — an estimated $231K sold.

Aperio Group first reported a position in DCPH in Q2 2019 and held it in 3 quarters. The position peaked at $231K in Q2 2020. 161 funds tracked by Wall St. Rank hold DCPH as of Q3 2020.

  • Aperio Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Aperio Group sold 3,860 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $231K.
  • Aperio Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Aperio Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $231K in Q2 2020.
  • 161 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Aperio Group's 13F filing for Q3 2020, filed 6 Nov 2020.